Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.

Detalles Bibliográficos
Autores principales: Mori, Nobuaki, Katayama, Mitsuya, Nukaga, Shigenari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534751/
https://www.ncbi.nlm.nih.gov/pubmed/33054978
http://dx.doi.org/10.1016/j.jmii.2020.09.003
Descripción
Sumario:No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.

Ejemplares similares